Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis

BACKGROUND: Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is currently in clinical trials for the treatment of hepatocellular carcinoma (HCC)....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Chen, Zhi-Yuan, Shi, Ming, Peng, Li-Xia, Wei, Wei, Li, Xin-Jian, Guo, Zhi-Xing, Li, Shu-Hong, Zhong, Chong, Qian, Chao-Nan, Guo, Rong-Ping
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2012
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3552726/
https://ncbi.nlm.nih.gov/pubmed/23228017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-245
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak